Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Bert Marchio
AddedFeb 15, 2024
UpdatedMay 1, 2026
Bert Marchio

Bert Marchio

Co-Founder, AOA Dx

Bert Marchio's Career

AOA Dx
AOA Dx

Boulder, CO, US

Co-Founder
Fresh Tracks Therapeutics
Fresh Tracks Therapeutics

Boulder, CO, US

CEO· C-Suite · Management

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Bert Marchio's Career

AOA Dx
AOA Dx
Series B$24.6M252020Boulder, CO, US
Co-Founder

Leadership at AOA Dx

Alex FisherAlex FisherCo-Founder
Alexander FischerAlexander FischerCo-Founder
Anna JeterAnna JeterCo-Founder
Oriana Papin-ZoghbiOriana Papin-ZoghbiFounder
Anna JeterAnna JeterFounder
Alexander FisherAlexander FisherCo-Founder
Fresh Tracks Therapeutics
Fresh Tracks Therapeutics
Public202009Boulder, CO, US
CEO· C-Suite · Management

Leadership at Fresh Tracks Therapeutics

Tim WollaegerTim WollaegerCo-Founder
Andrew SklawerAndrew SklawerCo-Founder
Gary LyonsGary LyonsBoard Member

Similar to Fresh Tracks Therapeutics

Chase TherapeuticsChase TherapeuticsWashington, D.C., DC, USPharmaceuticalsest. 2017Chase TherapeuticsWashington, D.C., DC, US · est. 2017

Chase Therapeutics: An early-stage pharmaceutical company innovating superior brain disease treatments.

Series B · $25.3M175
Aristea TherapeuticsAristea TherapeuticsSan Diego, CA, USDrugsest. 2018Aristea TherapeuticsSan Diego, CA, US · est. 2018

Aristea Therapeutics: Developing novel drugs for autoimmune and inflammatory diseases.

Series B · $117.6M75
Astria TherapeuticsAstria TherapeuticsBoston, MA, USBiopharmaceuticalsest. 2008Astria TherapeuticsBoston, MA, US · est. 2008

Astria Therapeutics, Inc.: A clinical-stage biopharmaceutical company developing treatments for rare diseases and lipid disorders.

Public · $656.4M24
PTC TherapeuticsPTC TherapeuticsSouth Plainfield, NJ, USPharmaceuticalsest. 1998PTC TherapeuticsSouth Plainfield, NJ, US · est. 1998

PTC Therapeutics, Inc.: A US-based pharmaceutical company specializing in oral, small-molecule drugs for genetic disorders, oncology, and infectious diseases.

Public · $1.6B1.4k

Bert Marchio's Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWillix HalimWillix HalimCEO · BukalapakBo ZhangBo ZhangCo-Founder · DiDiWILL WEI CHENGWILL WEI CHENGCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniFounder · Reliance RetailBrian KimBrian KimCo-Founder · KakaoKim Beom-sooKim Beom-sooCo-Founder · Kakao

People Similar to Bert Marchio

Paul BoniPaul BoniCo-Founder · AviridiChris LabaskyChris LabaskyCo-Founder · AboundJeff ReedJeff ReedFounder · TrackFiras KaddahFiras KaddahCo-Founder · FreshCreditChase SechristChase SechristCo-Founder · Tracks.byThomas AbertThomas AbertCo-Founder · ZS Genetics